Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), recently sold shares in the company valued at $3,000. The transaction, which took place on March 7, 2025, involved the sale of 100 shares of common stock at a price of $30.00 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan that Koch adopted on September 30, 2024. The timing is notable as the stock has shown strong momentum, gaining over 12% in the past week and 63% over the last six months, according to InvestingPro data.
In addition to the sale, Koch also acquired 100 shares of common stock through the exercise of stock options at a price of $0.18 per share, totaling $18. Following these transactions, Koch holds 14,478 shares directly. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with analysts recently revising their earnings expectations downward. Discover 10+ additional exclusive insights about EWTX with an InvestingPro subscription.
Koch also maintains indirect ownership through various trusts and the KTK Family Enterprise, LLC, where he serves as a manager or co-trustee. These holdings include 259,554 shares in the KTK Family Enterprise, LLC, and 26,410 shares each in the Nicole M. Soldow Heritage Trust, Adrienne R. Koch Heritage Trust, and Matthew K. Koch Heritage Trust. The company maintains strong liquidity with a current ratio of 19.93, indicating robust short-term financial health.
In other recent news, Edgewise Therapeutics has been the subject of multiple analyst evaluations and significant organizational changes. Piper Sandler has reiterated an Overweight rating with a $51 price target, emphasizing upcoming data releases for its EDG-7500 product, which could present a buying opportunity for investors. Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating, setting a $50 price target, citing promising early data from Edgewise’s drug candidates and their potential for commercialization. JPMorgan has also raised its price target to $45, maintaining an Overweight rating, based on anticipated positive results from the ongoing phase 2 CIRRUS-HCM study.
In terms of corporate developments, Edgewise Therapeutics announced the promotion of Behrad Derakhshan, Ph.D., to Chief Operating Officer, effective January 8, 2025, as part of a planned leadership transition. The company also appointed Robert Blaustein, M.D., Ph.D., as Chief Development Officer to lead the development of EDG-7500 and other pipeline projects. These leadership changes aim to bolster Edgewise’s late-stage clinical development efforts and prepare the company for commercial readiness. The company continues to focus on advancing its pipeline of therapies for serious muscle diseases, with several key data readouts anticipated.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.